A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
Status:
Active, not recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
The aim of this protocol is to find out about the safety and effectiveness of M2951 in
participants with relapsing multiple sclerosis. Participants were placed into 1 of 3 groups
to receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the participants on
placebo were given M2951.